Very recently, there were reported the results of the first clinical trials in patients with an immune disease, namely hepatitis C virus (HCV)-induced vasculitis [25], GVHD [23,24], or T1D [9,26], with a goal to induce Treg numbers and/or function with low-dose IL-2. The gene discussed is IL2; the disease is graft versus host disease.